PRESS RELEASE published on 11/04/2024 at 13:03, 1 year 3 months ago CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer CureVac appoints Axel Sven Malkomes as CFO, bringing 30 years of industry experience. His role will drive strategic initiatives, financial foundation, and shareholder value Biopharmaceutical Company CFO MRNA Technology CureVac Axel Sven Malkomes
PRESS RELEASE published on 11/04/2024 at 13:00, 1 year 3 months ago CureVac to Present at the 12th International mRNA Health Conference CureVac to present new data at the 12th International mRNA Health Conference, showcasing developments in mRNA cancer vaccine and lipid nanoparticle delivery technology Innovation Biopharmaceutical CureVac MRNA Platform MRNA Health Conference
BRIEF published on 10/28/2024 at 13:05, 1 year 3 months ago CureVac to Present New Findings at SITC Annual Meeting Clinical Trials MRNA Technology Cancer Vaccine CureVac SITC Meeting
PRESS RELEASE published on 10/28/2024 at 13:00, 1 year 3 months ago CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting CureVac to present at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, sharing immunogenicity data on mRNA-based cancer vaccine CVGBM. Conference details and contact info provided CureVac MRNA Poster Presentation Immunogenicity Society For Immunotherapy Of Cancer
BRIEF published on 09/13/2024 at 14:02, 1 year 4 months ago CureVac's CVGBM Cancer Vaccine Shows Promising Results in Phase 1 Glioblastoma Study CureVac Glioblastoma CVGBM Phase 1 Study T-cell Responses
PRESS RELEASE published on 09/13/2024 at 13:57, 1 year 4 months ago CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress CureVac's CVGBM Cancer Vaccine induces promising immune responses in Phase 1 Study in Glioblastoma presented at ESMO 2024 Congress. Results show de novo T-cell activity & acceptable safety profile up to 100 µg dose Cancer Vaccine CureVac CVGBM Phase 1 Study Immune Responses
BRIEF published on 09/12/2024 at 13:02, 1 year 4 months ago CureVac and GSK Report Positive Phase 2 Data for Influenza mRNA Vaccine MRNA Technology Influenza Vaccine Phase 2 Results GSK Partnership CureVac Milestone
PRESS RELEASE published on 09/12/2024 at 12:57, 1 year 4 months ago CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program CureVac Partner GSK reports positive Phase 2 results for seasonal influenza mRNA vaccine program. Data show immune responses to A and B strains with acceptable safety profile GSK CureVac Phase 2 MRNA Vaccine Seasonal Influenza
BRIEF published on 09/09/2024 at 13:05, 1 year 4 months ago CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress Clinical Data CureVac MRNA Vaccine Glioblastoma ESMO Congress
PRESS RELEASE published on 09/09/2024 at 13:00, 1 year 4 months ago CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress CureVac to present first CVGBM Glioblastoma cancer vaccine clinical data at ESMO 2024 Congress. First-in-human study results to be shared, highlighting mRNA technology's potential for cancer vaccines MRNA Technology CureVac Glioblastoma CVGBM ESMO 2024 Congress
Published on 02/07/2026 at 01:00, 1 day 6 hours ago Green Bridge Metals Can Help Secure U.S. Production of Critical Mineral Titanium
Published on 02/06/2026 at 23:10, 1 day 7 hours ago Topline Capital Management, LLC Announces Disposition of Shares of NamSys Inc.
Published on 02/06/2026 at 22:01, 1 day 9 hours ago Totec Resources Announces Listing of Shares on the Frankfurt Stock Exchange and Adoption of Omnibus Incentive Plan
Published on 02/06/2026 at 15:30, 1 day 15 hours ago Vulcan Minerals Inc. - Drilling Program Update for the Carbonear Zinc-Lead SEDEX project in Newfoundland
Published on 02/06/2026 at 13:30, 1 day 17 hours ago Redwood AI Corp. (formerly Marshall Technologies Corp.) Announces Closing of IPO and Listing of Shares on the Canadian Securities Exchange
Published on 02/07/2026 at 21:00, 10 hours 3 minutes ago Alibaba Group Debuts 'Wonder on Ice,' an Immersive AI Experience at Milan’s Sforza Castle for Milano Cortina 2026
Published on 02/07/2026 at 16:35, 14 hours 27 minutes ago The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies
Published on 02/07/2026 at 16:20, 14 hours 42 minutes ago NOTICE OF SETTLEMENT APPROVAL HEARING - SHORT FORM - WAYLAND GROUP CORP., SCOTT LANGILLE, GERHARD MÜLLER, PAUL PATHAK, ERIC SILVER, MICHAEL STEIN, JOHN DOES 1-3, CANACCORD GENUITY CORP., AND RF SECURITIES CLEARING LP (FORMERLY KNOWN AS GMP SECU
Published on 02/06/2026 at 19:25, 1 day 11 hours ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/06/2026 at 17:52, 1 day 13 hours ago EQS-Adhoc: Avemio AG: Preparation of the filing for insolvency proceedings by Teltec AG, a subsidiary of Avemio AG, and potential effects on the going-concern assessment of Avemio AG
Published on 02/06/2026 at 18:22, 1 day 12 hours ago Disclosure of Share Capital and Voting Rights as of January 31, 2026
Published on 02/06/2026 at 16:01, 1 day 15 hours ago Notice of exercise of early redemption option of the subordinated note ISIN : FR0010093328
Published on 02/05/2026 at 18:06, 2 days 12 hours ago Aéroports de Paris SA - Shares and voting rights as of 31 January 2026